“I see the development of Nanogen’s new bio-manufacturing facility and their absolutely state-of-the-art set of bioreactor purification systems. That will enable them to manufacture and make available, not just to Vietnam but to much of the rest of the world, a whole series of badly needed biosimilars, particularly recombinant proteins, monoclonal antibodies, and drugs.”
PROF. HARVEY F.LODISH
- Professor of Biology and Professor of Biological Engineering at MIT, USA
- Member of Whitehead Institute for Biomedical Research, USA
- Technical Advisor of NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC., Vietnam
“I see the development of Nanogen’s new bio-manufacturing facility and their absolutely state-of-the-art set of bioreactor purification systems. That will enable them to manufacture and make available, not just to Vietnam but to much of the rest of the world, a whole series of badly needed biosimilars, particularly recombinant proteins, monoclonal antibodies, and drugs.”